Craig Johnson

Craig currently serves as a director of Heron Therapeutics, Inc., La Jolla Pharmaceutical Company and Odonate Therapeutics, Inc. Craig has served as a member of the Mirati Board of Directors since 2013.

Craig served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018, Adamis Pharmaceuticals Corporation from 2011 to 2014, and Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. Between 2004 and 2009, Craig served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. Afterwards, he was Vice President of a wholly owned subsidiary of Raptor Pharmaceuticals Corp until 2010. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations.

Craig received a B.B.A. degree in accounting from the University of Michigan-Dearborn and practiced as a Certified Public Accountant with Price Waterhouse, now PricewaterhouseCoopers.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.